RUBICON ORGANICS INC

Rubicon Organics announces its September 24, 2026 AGM, reviewing 2025 finances, board elections, and future cannabis growth plans.

Rubicon Organics reports Q2 2026 growth, boosting revenue via Pacifica and new Cascadia facility, while solidifying its premium cannabis leadership across North America.

Explore Rubicon Organics: a TSX‑listed cannabis pharma company driving medical marijuana growth, tackling financial hurdles, and advancing specialty products.

Rubicon Organics opens its Cascadia facility, boosting specialty cannabis and organic pharma production while showing a low‑PE, undervalued stock poised for growth.

Rubicon Organics secures $4 million funding and hires former Aurora Cannabis CFO Glen Ibbott to drive premium cannabis growth and expand North American operations.

Rubicon Organics Inc is facing significant financial instability, with a negative P/E ratio and volatile stock price, raising concerns about its ability to thrive in the competitive cannabis market.

Rubicon Organics Inc, a cannabis company, faces financial challenges and regulatory uncertainty, raising questions about its sustainability and future prospects in the rapidly growing market.